New Private Facebook Discussion Groups
The Life Raft Group is launching two new private Facebook Support Groups for patients and their caregivers. These two groups are designed to provide a safe forum to discuss specific concerns in a closed [...]
Australian GIST Advocates Overcome Payer Obstacles Concerning Qinlock
Australian GIST Advocates Overcome Payer Obstacles Concerning Qinlock. 4th line drug approval was approved! GISTer Sarah McGoram shares the news.
Deciphera Announces Health Canada’s Authorization of QINLOCK™ (ripretinib) for the Treatment of 4L Gastrointestinal Stromal Tumor
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Health Canada has authorized QINLOCK™ (ripretinib), a switch-control tyrosine kinase inhibitor, for sale in Canada for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with imatinib, sunitinib, and regorafenib.
QINLOCK (ripretinib) – aprobado como cuarta línea de tratamiento para GIST
La FDA aprobó QINLOCKTM (ripretinib) para el tratamiento de adultos con tumor avanzado del estroma gastrointestinal (GIST) que han recibido 3 o más tratamientos previos para su GIST.
FDA Approves QINLOCK (ripretinib) by Deciphera for 4L GIST Patients
The FDA approved QINLOCKTM (ripretinib) for the treatment of adults with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more prior treatments for their GIST.